BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4Dose Level 4 exposure correlates with initial activity…